Oncor Revenue and Competitors

Oncor Inc. sold its 80% interest in Appligene Oncore, a French company, to a Canadian company for $1 million in February 1999. After the sale of Appligene, the Company\'s only remaining assets consisted of certain Oncor and Codon intellectual property and licenses. The future uses, if the Company is exploring any, of these remaining assets. In February 1999, Oncor, Inc. and its wholly-owned subsidiary, Codon Pharmaceuticals, Inc., filed voluntary petitions for relief under Chapter 11 of the United States Code with the United States Bankruptcy Court for the District of Delaware, Wilmington, Delaware. Oncor expects to reorganize under Chapter 11 and to propose a reorganization plan or plans. (Source: 10-K)